Interesting. It looks like on page 26 NNVC is counting Theracour's employees as its own. That is stretching the truth, to say the least. It seems NNVC tries to blur the line between Theracour and NNVC. It's almost as though they wanted investors to think that those 30 employees were busy creating patents and trade secrets for NNVC, and doesn't want investors to know that NNVC has no intellectual property, and is, in fact, not allowed to develop or manufacture nanoviricides, a privilege Theracour reserves for itself.
Market Data 
Markets 
